- Home
- ALEC vs NKTX Comparison
ALEC vs NKTX Comparison
Compare ALEC & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALEC | NKTX |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.2M | 133.5M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ALEC | NKTX |
|---|---|---|
| Price | $1.45 | $1.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $3.50 | ★ $13.25 |
| AVG Volume (30 Days) | ★ 1.7M | 641.1K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $69,048,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $160.66 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.26 | N/A |
| 52 Week Low | $0.87 | $1.31 |
| 52 Week High | $3.40 | $2.74 |
Technical Indicators
Market Signals| Indicator | ALEC | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.71 | 47.98 |
| Support Level | $1.18 | $1.78 |
| Resistance Level | $1.39 | $1.90 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 82.22 | 73.91 |
Price Performance
Historical ComparisonAbout ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.